With the settlement of a big acquisition behind them and a strong portfolio of therapeutics that continues to expand, hopes for smooth sailing are on the horizon.
Tag Archive for: Otezla
Amgen Inc. convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG’s Sandoz Inc until 2028.
Amgen is equipped with a broad and diverse product portfolio, commercial capabilities, and levers for delivering mid-single digit revenue growth over this decade.
Shares of ChemoCentryx are skyrocketing in premarket trading after the company announced it will be acquired by Amgen in a $4 billion deal that will bring Tavneos, a first-in-class treatment for ANCA-associated vasculitis, into the company’s portfolio.
